Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation. Our choice today is honeybush vanilla turmeric. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today and, of course, do keep in touch. …

Sanofi is experiencing shortages of two medicines used to treat Pompe disease, and the problem emerged shortly after the U.S. Food and Drug Administration warned the company over manufacturing issues at the Irish facility where the drugs are made, STAT reports. In recent days, the drugmaker has alerted patient groups and physicians in both the U.S. and Europe that supplies of Myozyme, an older standard of care, and Nexviazyme, a newer treatment, are dwindling due to what has been described as a bottleneck in the final manufacturing phase, as well as quality control issues at its Waterford plant.

Jazz Pharmaceuticals agreed to buy Actio Biosciences in a deal valued at ​up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that has no approved therapies, Reuters notes. The treatment, called ABS-1230, is being developed for KCNT1-related epilepsy, ​a severe disease that causes frequent seizures ​and developmental problems in children. KCNT1-related epilepsy affects about ​2,500 patients in the U.S., according to the company. ABS-1230 reduced seizures in ‌an ⁠early study of children and is being evaluated in a study intended to support a U.S. approval application.